SP-2-225
Solid Tumors
PreclinicalCandidate Lead
Key Facts
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals is a clinical-stage biotech focused on enhancing radiation therapy (RT) for cancer through novel small molecule therapies. Its mission is to increase cure rates and improve quality of life by developing targeted radiation sensitizers and protective agents. The company's strategy leverages a dual-platform approach of halogenated pyrimidines and selective HDAC inhibitors, with a lead Phase II candidate, Ropidoxuridine, in glioblastoma. Shuttle is advancing its pipeline through strategic academic collaborations and recently announced initiatives in AI for scientific workflows.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |
| MDG1021 | Medigene | Preclinical |